CalciMedica Inc. CALC

CalciMedica stock rose 6% after pulmonary hypertension progress offset a Q2 earnings miss. Pulmonary hypertension advancement signals pipeline strength that can lift near-term sentiment and valuation despite the earnings shortfall.

CalciMedica Inc. reported second quarter 2026 financial results along with clinical and corporate updates. Quarterly financial results and pipeline updates can moderately influence investor views on company progress.

CalciMedica announces FDA alignment on Phase 2b trial design for Auxora in acute pancreatitis and identifies the disease's first potential registrational endpoints. FDA alignment on Phase 2b design marks key regulatory progress for Auxora, likely boosting development trajectory and investor sentiment.

CalciMedica Inc. announces private placement financing for up to approximately $49 million to advance its pulmonary hypertension program. Financing delivers major capital to progress CalciMedica's core pulmonary hypertension program and strengthen its development runway.

CalciMedica announced FDA clearance to proceed with Auxora clinical development after review of KOURAGE trial interim safety data. FDA clearance to continue Auxora development marks key regulatory progress that can materially lift clinical timeline and valuation.

CalciMedica Inc. (CALC) reported first quarter 2026 financial results and provided updates on clinical trials and corporate progress. Quarterly financial results combined with clinical and corporate updates moderately influence financial performance and investor sentiment.

CalciMedica Inc. (CALC) reported 2025 financial results and provided clinical updates. Financial results combined with clinical updates represent major milestones that could drive stock volatility and long-term investor confidence.

CalciMedica Inc. experienced a dramatic 75% drop in its stock price following the termination of a trial related to acute kidney injury. The company announced that the trial did not meet its primary endpoint, leading to concerns about its future prospects and investor confidence. This significant decline reflects the market's reaction to the halted trial and its implications for CalciMedica's product development and financial stability. The termination of the trial fundamentally undermines the company's product pipeline and investor confidence.

CalciMedica Inc. (CALC) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and interest among investors. This surge in activity may be attributed to recent developments or market trends affecting the company, although specific details regarding these factors were not disclosed in the report. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential interest in the company's future performance.

CalciMedica Inc. has announced the discontinuation of its Phase 2 KOURAGE trial for acute kidney injury (AKI) following a recommendation from an independent Data Monitoring Committee. The decision was made based on the trial's interim results, which indicated that the treatment was unlikely to meet its primary endpoint. CalciMedica is now evaluating its next steps regarding the development of its product candidate. Discontinuation of the trial may moderately affect CalciMedica's financial performance and product pipeline.

CalciMedica Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and updates on clinical trials and corporate developments. The company continues to advance its pipeline, focusing on innovative treatments and strategic partnerships to enhance growth and market presence. Significant updates on clinical trials and corporate strategies are likely to influence investor sentiment and the company's future trajectory.

CalciMedica Inc. announced the publication of preclinical data in JCI Insight, supporting the potential of its CRAC channel inhibitor as a therapy for pulmonary arterial hypertension. The findings suggest that targeting CRAC channels may offer a new approach to treating this serious condition, which currently has limited treatment options. The research highlights the therapeutic promise of CalciMedica's innovative approach in addressing pulmonary arterial hypertension. The publication of preclinical data indicates significant potential for a new therapeutic approach, which could enhance CalciMedica's market position and investor interest.

CalciMedica Inc. presented data from a preclinical study of Auxora™ in an animal model of acute kidney injury (AKI) at ASN Kidney Week 2025. The study aimed to evaluate the efficacy and safety of Auxora™ in treating AKI, highlighting its potential benefits in this area. The findings contribute to the ongoing research and development efforts of CalciMedica in addressing kidney-related conditions. The presentation of preclinical data on Auxora™ could significantly influence investor sentiment and the company's strategic direction in the kidney treatment market.

CalciMedica Inc. has partnered with Telperian to incorporate an advanced artificial intelligence engine into the analysis of clinical trials for its drug Auxora™. This collaboration aims to enhance the evaluation process and improve outcomes in clinical research. The integration of AI into clinical trial analysis is a significant strategic move that could enhance product development and market positioning.

CalciMedica Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference, providing an opportunity for the company to engage with investors and showcase its developments. The conference is a platform for presenting the company's strategic initiatives and potential growth prospects to a broader audience. Participation in the conference may enhance investor engagement and sentiment, but it is not expected to significantly alter the company's trajectory.

CalciMedica Inc. reported its financial results for the second quarter of 2025, highlighting key metrics and updates on clinical trials and corporate developments. The company continues to advance its pipeline and maintain a strong financial position, with ongoing efforts to enhance product offerings and market presence. The financial results and clinical updates indicate moderate progress that may influence investor sentiment and operational aspects.

CalciMedica Inc. announced that CEO Rachel Leheny, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025. A live webcast will be available on the company's IR website, with a replay archived for 90 days. CalciMedica focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with its lead product candidate, Auxora™, showing positive results in clinical trials for conditions like acute pancreatitis and COVID pneumonia. The company is currently conducting a Phase 2 trial for acute kidney injury. Participation in a significant conference may enhance visibility and investor interest, impacting market sentiment moderately.

CalciMedica Inc. announced the publication of a study in the American Journal of Nephrology detailing the design and rationale behind the Phase 2 KOURAGE trial of Auxora™ for treating acute kidney injury (AKI) with respiratory failure. The trial aims to evaluate the efficacy and safety of Auxora™ in this patient population, highlighting its potential therapeutic benefits. The publication of the trial design indicates significant progress in clinical development, which could enhance investor sentiment and market positioning.

Insiders at CalciMedica Inc. have purchased a total of US$1.05 million in company stock, indicating confidence in the firm's future prospects. This insider buying activity may reflect positive sentiment regarding the company's performance and growth potential. Insider purchases can signal confidence in the company's future, potentially influencing market sentiment and stock performance.

CalciMedica Inc. announced its participation in the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting, where it will present its latest research and developments in critical care nephrology. The symposium aims to enhance understanding and treatment of acute kidney injury and continuous renal replacement therapy, showcasing advancements in the field. Participation in significant medical symposiums can enhance visibility and credibility, potentially influencing future collaborations and market perception.

CalciMedica Inc. reported its financial results for the first quarter of 2025, highlighting key metrics and updates on clinical trials and corporate initiatives. The company continues to advance its product pipeline and is focused on enhancing its market position. Financial performance showed growth, and management provided insights into future strategies and expected developments in ongoing clinical studies. Significant updates on clinical trials and financial performance indicate a strong potential for future growth and market impact.

CalciMedica Inc. announced the acceptance of an abstract for a poster presentation at Digestive Disease Week 2025 and the participation of its Chief Medical Officer in an oral presentation and panel discussion at the American Society of Nephrology conference. The poster will focus on patients with acute pancreatitis and systemic inflammatory response syndrome, while the oral presentation will cover experiences with acute kidney injury clinical trial design. The company is developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with ongoing clinical trials for its lead product candidate, Auxora™. Participation in major medical conferences and the focus on acute kidney injury and pancreatitis could significantly enhance CalciMedica's visibility and credibility in the biopharmaceutical sector.

CalciMedica Inc. announced that CEO Rachel Leheny, Ph.D., will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with its lead product candidate, Auxora™, showing positive results in clinical trials. Ongoing trials include a Phase 2b study in acute pancreatitis and a Phase 2 trial in acute kidney injury, with updates expected in 2025. The upcoming conference presentation and ongoing clinical trials may moderately influence investor sentiment and the company's competitive positioning.

CalciMedica Inc. reported its financial results for 2024, highlighting key clinical and corporate updates. The company provided insights into its ongoing projects and future plans, emphasizing advancements in its product pipeline and strategic initiatives aimed at enhancing market presence and operational efficiency. Significant updates on clinical progress and corporate strategy are likely to influence investor sentiment and the company's future trajectory.

CalciMedica Inc. has secured a credit facility of up to $32.5 million to support its ongoing operations and development efforts. The financing is expected to enhance the company's liquidity and provide additional resources for advancing its clinical programs. This strategic move aims to bolster CalciMedica's financial position as it continues to focus on its innovative therapies. Securing a significant credit facility is likely to enhance the company's operational capabilities and financial stability, impacting its future performance.

CalciMedica Inc. presented data from a post-hoc analysis of the Phase 2 CARDEA trial of Auxora™ for treating severe COVID-19 pneumonia at the 30th International AKI & CRRT Conference. The analysis focused on acute kidney injury (AKI) outcomes, highlighting the potential benefits of Auxora™ in this patient population. The findings aim to support further development and regulatory considerations for the drug. The presentation of significant clinical data could influence investor sentiment and strategic direction for CalciMedica.

CalciMedica Inc. announced a plenary presentation at the 30th International AKI & CRRT Conference, scheduled for March 3-6, 2025, in San Diego, CA. The presentation, titled 'The Role of ORAI-1 in AKI,' will be delivered by Dr. Sudarshan Hebbar, Chief Medical Officer. CalciMedica focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, with its lead product candidate, Auxora™, showing positive results in clinical trials for conditions like acute pancreatitis and COVID pneumonia. The company is also conducting trials for acute kidney injury and pediatric patients with asparaginase-induced pancreatic toxicity. The upcoming presentation could significantly enhance CalciMedica's visibility and credibility in the medical community, potentially impacting its market performance.

CalciMedica Inc. has appointed Dr. Alan Glicklich to its Board of Directors. Dr. Glicklich brings extensive experience in the biopharmaceutical industry, having held leadership roles in various companies. His expertise is expected to enhance CalciMedica's strategic direction and governance as the company advances its clinical programs and product development. The appointment of Dr. Glicklich is likely to influence CalciMedica's strategic direction and governance, which may positively affect its operations and market perception.

CalciMedica Inc. announces presentations at upcoming medical meetings for Phase 2b CARPO trial of Auxora in Acute Pancreatitis. The announcement of presentations at medical meetings for a Phase 2b trial could have a significant impact on CalciMedica's future and market performance.

CalciMedica Inc. reported their third quarter 2024 financial results and provided clinical and corporate updates. The financial results and updates are expected to moderately influence key areas like financial performance and competitive positioning.